Lymphoma and Non-Acute Leukemia DRG 823 Reimbursement

DRG 823 applies to inpatient hospitalizations for lymphoma and non-acute leukemia when other significant procedures are performed and a Major Complication or Comorbidity is present. This Diagnosis-Related Group reflects higher resource use and influences Medicare inpatient reimbursement by assigning a higher payment weight for cases with major complications and additional procedures.

DRG 823 Overview

DRG 823 covers inpatient stays for patients with lymphoma and non-acute leukemia who undergo other significant procedures and have a Major Complication or Comorbidity. This category captures higher-resource hospitalizations where additional operative or procedural care substantially affects costs. It is important for Medicare payment because the presence of a Major Complication or Comorbidity and qualifying procedures increase reimbursement relative to less complex groups. Accurate coding of principal diagnosis, procedures, and complications determines assignment to this Diagnosis-Related Group and the associated payment weight.

DRG 823 Overview

Studies of intensive inpatient chemotherapy regimens and supportive-care bundles for patients with high-burden lymphoma or chronic/non-acute leukemias who require complex procedures: these trials evaluate dose-intense or combination chemotherapy delivered in the inpatient setting plus protocolized infection prophylaxis, transfusion strategies, and management of tumor lysis or marrow suppression. The patient population includes those admitted for myelosuppressive therapy or procedural interventions (e.g., central venous access, biopsies, or plasmapheresis) with major complications (MCC) that increase length of stay and resource use. Results inform clinicians and payers about inpatient resource intensity, complication rates, and short-term outcomes that drive DRG cost and reimbursement considerations.
Comparative effectiveness studies of alternative procedural approaches and peri-procedural risk mitigation for lymphoma/non-acute leukemia patients undergoing invasive procedures: these trials compare techniques such as image-guided biopsy, different vascular access strategies, or variations in transfusion and antimicrobial protocols to reduce procedure-related morbidity. The focus population is patients categorized under this DRG because they undergo “other procedures” and present with comorbidities or complications that qualify as MCC; endpoints include procedure-related complications, readmissions, and ICU transfers. Findings are relevant to providers and payers by identifying protocols that reduce complications, shorten hospital stay, and lower downstream costs associated with MCC events.
Post-discharge outcomes and care-transition trials targeting readmission prevention and functional recovery after hospitalization for lymphoma or non-acute leukemia with major complications: these studies test structured discharge planning, outpatient monitoring pathways, early hematology clinic follow-up, and symptom-management interventions to detect infection, bleeding, or treatment toxicity early. They enroll patients recently discharged after an admission coded to this DRG, especially those with prolonged index stays or significant in-hospital procedures, and measure 30–90 day readmissions, emergency visits, and patient-reported outcomes. Payers and health systems use this evidence to design care bundles that reduce readmissions and total cost-of-care while maintaining quality for a high-risk cohort.

Studies of intensive inpatient chemotherapy regimens and supportive-care bundles for patients with high-burden lymphoma or chronic/non-acute leukemias who require complex procedures: these trials evaluate dose-intense or combination chemotherapy delivered in the inpatient setting plus protocolized infection prophylaxis, transfusion strategies, and management of tumor lysis or marrow suppression. The patient population includes those admitted for myelosuppressive therapy or procedural interventions (e.g., central venous access, biopsies, or plasmapheresis) with major complications (MCC) that increase length of stay and resource use. Results inform clinicians and payers about inpatient resource intensity, complication rates, and short-term outcomes that drive DRG cost and reimbursement considerations.
Comparative effectiveness studies of alternative procedural approaches and peri-procedural risk mitigation for lymphoma/non-acute leukemia patients undergoing invasive procedures: these trials compare techniques such as image-guided biopsy, different vascular access strategies, or variations in transfusion and antimicrobial protocols to reduce procedure-related morbidity. The focus population is patients categorized under this DRG because they undergo “other procedures” and present with comorbidities or complications that qualify as MCC; endpoints include procedure-related complications, readmissions, and ICU transfers. Findings are relevant to providers and payers by identifying protocols that reduce complications, shorten hospital stay, and lower downstream costs associated with MCC events.
Post-discharge outcomes and care-transition trials targeting readmission prevention and functional recovery after hospitalization for lymphoma or non-acute leukemia with major complications: these studies test structured discharge planning, outpatient monitoring pathways, early hematology clinic follow-up, and symptom-management interventions to detect infection, bleeding, or treatment toxicity early. They enroll patients recently discharged after an admission coded to this DRG, especially those with prolonged index stays or significant in-hospital procedures, and measure 30–90 day readmissions, emergency visits, and patient-reported outcomes. Payers and health systems use this evidence to design care bundles that reduce readmissions and total cost-of-care while maintaining quality for a high-risk cohort.

OpenPayer

Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

Sign up for Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview policy alerts

DRG 823 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

Sign up for Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview policy alerts

DRG 823 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References